Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 8, 2025
Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II (COSIRA-II)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 15, 2025
Endocardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment: A 26-Week (with 26 Week Extension) Phase 2b Randomized, Multi-Center, Double-Blind, Sham Controlled Study to Evaluate Efficacy and Safety (The EXACT-2 Trial)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 15, 2025
The Magenta Elevate™ High-Risk PCI Pivotal Study (Elevate III)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 15, 2025
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 7, 2025
A Phase III, Open-label, Randomised Study of Osimertinib With or Without Dato-DXd as First-line Treatment in Participants With Epidermal Growth Factor Receptor Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 7, 2025
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd)
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 8, 2025
A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects with Moderate to Severe Atopic Dermatitis (AD) and Inadequate Response to Dupilumab (SWITCH-UP)
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 8, 2025
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects with Multiple Myeloma
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 8, 2025
Repository of Novel Analytes Leading to Autoimmune, Inflammatory, and Diabetic Nephropathies (RENAL AID)
Study Status:
Open to Enrollment
Primary Investigator:
Alan Perlman, M.D.
Date: March 15, 2016